Advanced search
Publication Cover
Clinical and Experimental Gastroenterology Volume 16, 2023 - Issue
Submit an article Journal homepage
602
Views
0
CrossRef citations to date
0
Altmetric
CASE SERIES

PSMA-Targeted PET Radiotracer [18F]DCFPyL as an Imaging Biomarker in Inflammatory Bowel Disease

Mohamed Saleh Ismail1 Division of Gastroenterology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
,
Diane E Peters2 Department of Pharmacology and Molecular Sciences, Johns Hopkins Medical Institutions, Baltimore, MD, USA;3 Johns Hopkins Drug Discovery, Baltimore, MD, USA
,
Steven P Rowe4 Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA;5 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA
,
Ali Salavati6 Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA
,
Sowmya Sharma1 Division of Gastroenterology, Johns Hopkins Medical Institutions, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0002-3803-1537
ORCID Icon,
Robert A Anders7 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medical Institutions, Baltimore, MD, USA
,
Martin Pomper2 Department of Pharmacology and Molecular Sciences, Johns Hopkins Medical Institutions, Baltimore, MD, USA;4 Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD, USA;5 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USAORCID Iconhttps://orcid.org/0000-0001-6753-3010
ORCID Icon,
Barbara S Slusher2 Department of Pharmacology and Molecular Sciences, Johns Hopkins Medical Institutions, Baltimore, MD, USA;3 Johns Hopkins Drug Discovery, Baltimore, MD, USA;8 Department of Neurology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
&
Florin M Selaru1 Division of Gastroenterology, Johns Hopkins Medical Institutions, Baltimore, MD, USA;5 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USACorrespondence[email protected] [email protected]
 show all
Pages 237-247 | Received 01 Mar 2023, Accepted 03 Aug 2023, Published online: 08 Dec 2023

References

  • Liverani E, Scaioli E, Digby RJ, Bellanova M, Belluzzi A. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol. 2016;22(3):1017–1033. doi:10.3748/wjg.v22.i3.1017
  • Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):351–361 e355. doi:10.1053/j.gastro.2016.09.046
  • Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338. doi:10.1038/ajg.2015.233
  • Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) Initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi:10.1053/j.gastro.2020.12.031
  • Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426–431. doi:10.1136/gut.2005.069476
  • Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis. 2014;8(12):1582–1597. doi:10.1016/j.crohns.2014.08.011
  • Vornov JJ, Peters D, Nedelcovych M, et al. Looking for drugs in all the wrong places: use of GCPII Inhibitors Outside the Brain. Neurochem Res. 2020;45(6):1256–1267. doi:10.1007/s11064-019-02909-y
  • Rais R, Jiang W, Zhai H, et al. FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. JCI Insight. 2016;1(12). doi:10.1172/jci.insight.88634.
  • Slusher RR, Li X. Methods for Treating Inflammatory Bowel Disease Using Prostate Specific Membrane Antigen (PSMA) Inhibitors (US); 2015.
  • Peters DE, Norris LD, Slusher BS. Spontaneous loss-of-function Dock2 mutation alters murine colitis sensitivity and is a confounding variable in inflammatory bowel disease research. Crohn Colitis. 2019;360:1.
  • Vornov JJ, Hollinger KR, Jackson PF, et al. Still NAAG’ing after all these years: the continuing pursuit of GCPII Inhibitors. Adv Pharmacol. 2016;76:215–255.
  • de Galiza Barbosa F, Queiroz MA, Nunes RF. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20(23). doi:10.1186/s40644-020-00300-7
  • Troyer JK, Beckett ML, Wright GL. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62(5):552–558. doi:10.1002/ijc.2910620511
  • Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50(4):472–483. doi:10.1111/j.1365-2559.2007.02635.x
  • Haffner MC, Kronberger IE, Ross JS, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol. 2009;40(12):1754–1761. doi:10.1016/j.humpath.2009.06.003
  • Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg. 2006;30(4):628–636. doi:10.1007/s00268-005-0544-5
  • Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–85.
  • Zhang T, Song B, Zhu W, et al. An ileal crohn’s disease gene signature based on whole human genome expression profiles of disease unaffected ileal mucosal biopsies. PLoS One. 2012;7(5):e37139. doi:10.1371/journal.pone.0037139
  • Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG. GCPII imaging and cancer. Curr Med Chem. 2012;19(9):1346–1359. doi:10.2174/092986712799462612
  • Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17(24):7645–7653. doi:10.1158/1078-0432.CCR-11-1357
  • Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-Targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565–574. doi:10.1007/s11307-015-0850-8
  • Chandekar KR, Tanigassalam S, Kavanal AJ, et al. [68 Ga]Ga-PSMA-11 small bowel uptake in crohn’s disease: revisiting the “Non-specificity” of PSMA ligands. Nucl Med Mol Imaging. 2022;56(2):102–104. doi:10.1007/s11307-015-0850-8
  • Nováková Z, Foss CA, Copeland BT, et al. Novel monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) as research and theranostic tools. Prostate. 2017;77(7):749–764. doi:10.1002/pros.23311
  • Ince MN, Elliott DE. Effective use of the laboratory in the management of patients with inflammatory bowel diseases. Gastroenterol Clin North Am. 2019;48(2):237–258. doi:10.1016/j.gtc.2019.02.006
  • Chang S. Disease monitoring in inflammatory bowel disease. World J Gastroenterol. 2015;21(40):11246–11259. doi:10.3748/wjg.v21.i40.11246
  • D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218–2224. doi:10.1002/ibd.22917
  • Garcia-Sanchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis. 2010;4(2):144–152. doi:10.1016/j.crohns.2009.09.008
  • Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982–1018. doi:10.1016/j.crohns.2013.09.016
  • Kothari ST, Huang RJ, Shaukat A, et al. ASGE review of adverse events in colonoscopy. Gastrointest Endosc. 2019;90(6):863–876 e833. doi:10.1016/j.gie.2019.07.033
  • Panés J, Bouzas R, Chaparro M, et al., Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease. Alimentary Pharmacology & Therapeutics. 2011;34(2):125–145. doi:10.1111/j.1365-2036.2011.04710.x
  • Loftus EV.Using CT and MR enterography to diagnose and monitor IBD. Gastroenterol Hepatol. 2010;6(12):754–756.
  • Lapp RT, Spier BJ, Perlman SB, et al. Clinical utility of positron emission tomography/computed tomography in inflammatory bowel disease. Mol Imaging Biol. 2011;13(3):573–576. doi:10.1007/s11307-010-0367-0
  • Date AA, Rais R, Babu T, et al. Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease. J Control Release. 2017;263:132–138. doi:10.1016/j.jconrel.2017.01.036

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.